CMS to deploy drug price negotiation framework | Study examines efficacy of supplements | AI vendor hit by data breach

As the Medicare drug price negotiation program enters its fourth year next year, regulators are looking to put a set of guidelines in place that make it clear how medications are selected for inclusion and what the deliberation process will look like for biopharma companies.

Some of today’s most popular products promise better immune, adaptogenic, anti-inflammatory, gut, skin or joint health—or combinations of two or more of the above.  

Tennessee-based Xsolis said the incident occurred in January, and the sensitive data was from its clients. The company provides AI-powered case management software to hospitals and health insurers.

The company called the state’s regulation of pharmacy benefit managers “shortsighted,” as it would force the closure of Accredo, a specialty drug dispensary that supplies drugs it says aren’t available anywhere else in the state.

The agency had been suing the three largest pharmacy benefit managers over their alleged control of insulin prices. It reached agreements with CVS’ Caremark and Cigna’s Express Scripts earlier this year.

The collaboration between the chipmaker and Abridge, a developer of generative AI for healthcare, will involve data-sharing to improve Nvidia’s general-purpose models, which in turn will be used to make Abridge’s clinical offerings more efficient.

Anthony Weinert, DPM, said the reputational harm he suffered as a result of the 2019 healthcare fraud charges has left him unable to find work, despite the case being voluntarily withdrawn by authorities.

A team of healthcare scholars is making U.S. states an offer they hope the border-defined polities won’t refuse: If you’ll pay for the reinvention of primary care, we’ll help sell the public on the rightness of measured, state-level efforts to preserve the profession.

In an email, the Centers for Disease Control and Prevention asked workers to consider supporting screenings of at-risk individuals arriving stateside. The move follows a formal recognition of the ongoing Ebola outbreak in Africa as a Level 2 emergency, meaning the U.S. will have to take certain precautions to keep the virus from entering the country.

This recall was put in place due to a risk of the included adhesive not working. Nothing needs to be returned, but clinicians should not use the adhesive that comes inside the procedure kits.

Virginia Medical Imaging filed the complaint against Mary Washington Healthcare on June 5 in a Fredericksburg Circuit Court, seeking nearly $3 million in damages.